Journal of Radiotherapy in Practice is a peer-reviewed journal published by Cambridge University Press, focusing on the evolving field of radiotherapy and its application in clinical practice. With ISSN 1460-3969 and E-ISSN 1467-1131, this journal serves as a critical platform for researchers, clinicians, and students in oncology and radiology, providing vital insights into treatment methodologies, patient care, and innovative practices. Although indexed in Q4 quartiles for both Oncology and Radiology, Nuclear Medicine and Imaging, the journal plays an essential role in disseminating clinical findings and advancing the science of radiotherapy since its inception in 1999. Authors are encouraged to contribute their research, case studies, and reviews that align with the journal's objectives, fostering a collaborative environment for sharing knowledge. Despite its current rankings, the journal aims to enhance its impact and visibility in the scientific community, thereby enriching professional practice and patient outcomes in the realm of radiotherapy.

Journal of Thoracic Oncology, published by Elsevier Science Inc, is a premier scholarly outlet dedicated to advancing the field of thoracic oncology. With an impressive impact factor and consistently rated in the Q1 quartile across several pertinent categories such as Medicine, Oncology, and Pulmonary and Respiratory Medicine, this journal stands at the forefront of research dissemination. Covering a broad scope that includes innovative therapeutic approaches, clinical trials, and the molecular underpinnings of thoracic malignancies, the journal serves as a vital resource for researchers, healthcare professionals, and students seeking to enhance their understanding of thoracic cancer and its treatment. With publication dates converging from 2006 to 2024, the Journal of Thoracic Oncology fosters a collaborative scholarly community by providing a platform for high-quality research while ensuring accessibility through traditional publication formats. Positioned in the heart of New York City, this journal not only reflects the cutting-edge advancements in oncology but also plays a pivotal role in shaping the future of thoracic cancer care.

STRAHLENTHERAPIE UND ONKOLOGIE is an esteemed journal published by Springer Heidelberg, focusing on critical advancements and research in the fields of Oncology and Radiology. Established in 1986, this journal has carved its niche within the scientific community, ranking in the Q1 category for Radiology, Nuclear Medicine and Imaging, and Q2 for Oncology as of 2023. With an ISSN of 0179-7158 and E-ISSN 1439-099X, it serves as an essential resource for researchers, professionals, and students dedicated to the complexities of cancer treatment and radiation therapy. While the journal operates under a subscription model, its broad international readership values its rigorous peer-review process and comprehensive coverage of pivotal studies. STRAHLENTHERAPIE UND ONKOLOGIE continues to enhance its impact in the domains of oncology and radiology, as evidenced by its commendable Scopus rankings, including a 76th percentile in Radiology and a 65th percentile in Oncology. Its commitment to disseminating innovative research solidifies its role as a cornerstone in the ongoing quest to improve patient care and therapeutic techniques.

PROSTATE CANCER AND PROSTATIC DISEASES, published by SpringerNature, is a prestigious international journal dedicated to advancing knowledge in the fields of cancer research, oncology, and urology, as evidenced by its Q1 rankings in 2023. Established in 1997, this journal has become a vital resource for researchers, clinicians, and healthcare professionals, offering impactful research and clinical insights on prostate health and disease. With its focus on innovative studies and comprehensive reviews, it addresses critical challenges in the management and treatment of prostate cancer, driving improvements in patient care globally. The journal's standing is further supported by its impressive Scopus rankings, placing it in the top tier of its categories. Readers can access high-quality, peer-reviewed articles that contribute significantly to ongoing medical practices and improve therapeutic strategies for prostate-related health issues.

Turk Onkoloji Dergisi - Turkish Journal of Oncology, published by KARE PUBL, serves as a vital platform in the field of oncology, specifically catering to the Turkish-speaking research community and contributing to global discourse. With an ISSN of 1300-7467, this journal, which has been in circulation since 2007 and continues until 2024, recognizes the importance of advancing medical knowledge in cancer research through rigorous peer-reviewed articles. Although currently positioned in the Q4 category of oncology journals with a Scopus rank of #344 out of 404, the journal is dedicated to fostering significant research insights and innovative perspectives on cancer treatment and prevention. While it does not currently offer open access, its content is essential for professionals, researchers, and students aiming to enhance their understanding of oncology developments in Turkey and beyond. The Turkish Journal of Oncology not only aspires to improve the quality of cancer care but also strives to enhance collaboration among researchers, thereby influencing future oncology practices.

ACTA ONCOLOGICA is a prestigious multidisciplinary journal published by Medical Journal Sweden AB, dedicated to advancing cancer research and clinical practice. As a key resource in the field of oncology, the journal aims to publish high-quality articles that cover significant developments in cancer biology, treatment modalities, and innovative imaging techniques. With an ISSN of 0284-186X and an E-ISSN of 1651-226X, ACTA ONCOLOGICA operates in the United Kingdom and is recognized for its substantial impact, currently holding a Q2 ranking in the categories of Hematology, Medicine (miscellaneous), Oncology, and Radiology, Nuclear Medicine and Imaging in 2023. The journal’s commitment to disseminating pivotal research is reflected in its inclusion in Scopus, with rankings placing it in the top half of its fields. Though it does not currently offer Open Access, it remains an essential resource for researchers, healthcare professionals, and students seeking to stay informed on the latest trends and findings in oncology. Established in 1963, the journal continues to be a cornerstone of cancer research well into 2024.

INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, published by Taylor & Francis Ltd, has established itself as a premier forum for the dissemination of innovative research related to radiation biology, covering emerging topics that are crucial within the fields of radiology, nuclear medicine, and ultrasound technology. With an ISSN of 0955-3002 and an E-ISSN of 1362-3095, this journal spans over six decades, from its inception in 1959 to 2024, reflecting a rich history of scholarly contribution and a dynamic approach to addressing current challenges in the discipline. Its reputation is highlighted by its Q2 rankings in both Radiology, Nuclear Medicine and Imaging and Radiological and Ultrasound Technology for 2023, underscoring its relevance in a competitive academic landscape, with Scopus rankings placing it in the top tier of its category. While operating under a traditional access model, the journal aims to connect researchers, professionals, and students, facilitating the advancement of knowledge and fostering a deeper understanding of the impact of radiation in various medical applications. The journal plays an essential role in shaping future research directions and enhancing clinical practices globally.

Radiation Oncology Journal, published by the Korean Society of Therapeutic Radiology & Oncology, stands at the forefront of cancer treatment research and innovation within the dynamic fields of oncology and radiology. With a focus on disseminating groundbreaking findings and advancements from 2012 to 2024, this journal aims to foster collaboration among researchers, clinicians, and educators dedicated to improving therapeutic techniques and patient outcomes in the context of radiation therapy. Recognized with a prestigious Q2 ranking in both the Oncology and Radiology, Nuclear Medicine and Imaging categories, it ranks 140th out of 333 in its Scopus category for Medicine Radiology and boasts a 58th percentile placement. While operating on a non-open access basis, the journal remains committed to providing valuable insights and updates to professionals in the field from its base in South Korea. As the landscape of cancer treatment evolves, the Radiation Oncology Journal continues to play a vital role in shaping research trends and enhancing the understanding of radiotherapy's role in comprehensive cancer care.

Translational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.

Current Breast Cancer Reports is a vital academic journal published by Springer that focuses on the latest research and advancements in the field of breast cancer. With its ISSN 1943-4588 and E-ISSN 1943-4596, this journal serves as an essential resource for oncologists, researchers, and healthcare professionals dedicated to improving diagnosis and treatment strategies for breast cancer. Spanning from 2009 to 2024, it provides a platform for high-quality, peer-reviewed articles that encompass a range of topics, including molecular biology, clinical trials, and innovative therapeutic approaches. Although it is currently classified in the Q3 category in Oncology and is positioned in the 29th percentile, the journal remains committed to elevating its academic impact and contributing meaningfully to the ongoing fight against breast cancer. As it seeks to disseminate critical findings and foster collaboration within the scientific community, Current Breast Cancer Reports is poised to be an indispensable tool for anyone keen on advancing the field.